Cargando…

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and ele...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergara-Jimenez, Jennifer, Tricoci, Pierluigi
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/
https://www.ncbi.nlm.nih.gov/pubmed/20234778
_version_ 1782178632322514944
author Vergara-Jimenez, Jennifer
Tricoci, Pierluigi
author_facet Vergara-Jimenez, Jennifer
Tricoci, Pierluigi
author_sort Vergara-Jimenez, Jennifer
collection PubMed
description Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and elective PCI. This large amount of information provides a clear efficacy and safety profile of the drug, although a few questions on the use of abciximab still exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic medications. In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI.
format Text
id pubmed-2835553
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28355532010-03-16 Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention Vergara-Jimenez, Jennifer Tricoci, Pierluigi Vasc Health Risk Manag Review Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and elective PCI. This large amount of information provides a clear efficacy and safety profile of the drug, although a few questions on the use of abciximab still exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic medications. In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI. Dove Medical Press 2010 2010-03-03 /pmc/articles/PMC2835553/ /pubmed/20234778 Text en © 2010 Vergara-Jimenez and Tricoci, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Vergara-Jimenez, Jennifer
Tricoci, Pierluigi
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
title Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
title_full Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
title_fullStr Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
title_full_unstemmed Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
title_short Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
title_sort safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/
https://www.ncbi.nlm.nih.gov/pubmed/20234778
work_keys_str_mv AT vergarajimenezjennifer safetyandefficacyofabciximabasanadjuncttopercutaneouscoronaryintervention
AT tricocipierluigi safetyandefficacyofabciximabasanadjuncttopercutaneouscoronaryintervention